ROTH Capital Partners Acts as Joint Book-Running Manager
for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
in its $10 Million Follow-On

For more information please contact:

Investment Banking
John Chambers
Vice-Chairman and
Head of Healthcare
Investment Banking

(646) 358-1901
jchambers@roth.com


Michael Margolis, R.Ph
Managing Director
(646) 358-1902
mmargolis@roth.com

 

Warren Dunnavant II
Director
(646) 358-1903
wdunnavant@roth.com

Equity Capital Markets
Aaron Gurewitz
Head of Equity
Capital Markets
(949) 720-5703

agurewitz@roth.com

 

Nazan Akdeniz
Senior Vice President
(949) 720-5740

nakdeniz@roth.com

 

Lou Ellis
Senior Vice President
(949) 720-5739

lellis@roth.com

Transaction Information

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has completed an underwritten public offering of 5,000,000 shares of its common stock at a price of $2.00 per share. Tonix has also granted to the underwriters a 45-day option to acquire an additional 750,000 shares to cover overallotments in connection with the offering.

   

Tonix expects to use the net proceeds of the offering to support the continued development of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia, including the completion of the AFFIRM and RE-AFFIRM studies, to further develop TNX-102 SL for the treatment of post-traumatic stress disorder, to further develop our other pipeline programs, and for working capital and other general corporate purposes, and possibly acquisitions of other companies, products or technologies, though no such acquisitions are currently contemplated.

   

ROTH Capital Partners acted as joint book-running managers for the offering.

 

About Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp. is developing next-generation medicines for common disorders of the central nervous system, including fibromyalgia and post-traumatic stress disorder. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. For more information, please visit www.tonixpharma.com. (Source: Company Press Release | 6/16/16)

 

About ROTH Capital Partners

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. For more information on ROTH, please visit www.roth.com.

About ROTH Investment Banking Venture Finance Institutional Sales & Trading
Research Corporate Services Marketing & Conferences Press Room

The material, information and  facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC ("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of ROTH. Copyright 2016.